U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry October 2017

Draft

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2017-D-5767
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

This guidance is intended to assist potential applicants in determining when an application for a 14 synthetic peptide drug product (synthetic peptide) that refers to a previously approved peptide 15 drug product of recombinant deoxyribonucleic acid (rDNA) origin (peptide of rDNA origin) 16 should be submitted as an abbreviated new drug application (ANDA) under section 505(j) of the 17 Federal Food, Drug, and Cosmetic Act (FD&C Act) rather than as a new drug application (NDA) 18 under section 505(b) of the FD&C Act. Specifically, this guidance covers the following five 19 peptide drug products: glucagon, liraglutide, nesiritide, teriparatide, and teduglutide.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2017-D-5767.

Back to Top